# The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis

> **NCT01067326** · PHASE3 · TERMINATED · sponsor: **Mayo Clinic** · enrollment: 22 (actual)

## Conditions studied

- Endothelial Dysfunction

## Interventions

- **DRUG:** Aliskiren
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01067326
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-02
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 22 (ACTUAL)
- **Why stopped:** Novartis ended all studies regarding Aliskiren.
- **Last updated:** 2013-02-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01067326

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01067326, "The Effect of Tekturna on Endothelial Function and Endothelial Progenitor Cells in Patients With Early Atherosclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01067326. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*